Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | April 08, 2021 | April 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
OnKure Therapeutics, Inc.
Report date April 08, 2021 · Filed April 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2031-04-07 | Direct | 14,000 |
Reported balance
After 2021-04-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-08 · Grant · Acquired 14,000 · Balance 14,000 F1: The shares subject to the option vest on April 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on April 8, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001854337-26-000004 · form4-06172026_080618.xml · derivative · entry 2 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 3,772 | $0.00 Strike: $101.00 | $0.00 |
DisclosureSEC source: 0001854337-26-000004 · form4-06172026_080618.xml · derivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001854337-26-000002 · form4-06022026_070605.xml · derivative · entry 2 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 3,977 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001854337-26-000002 · form4-06022026_070605.xml · nonDerivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:34 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015301 · form4-06022025_110626.xml · derivative · entry 4 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Underlying: Common Stock · 3,977 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:34 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 6,268 | $0.00 Strike: $44.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015301 · form4-06022025_110626.xml · derivative · entry 3 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,268 Underlying: Common Stock · 6,268 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:34 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015301 · form4-06022025_110626.xml · derivative · entry 2 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:34 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015301 · form4-06022025_110626.xml · nonDerivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:23 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016069 · form4-06072024_100643.xml · derivative · entry 2 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:23 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 8,779 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001415889-24-016069 · form4-06072024_100643.xml · derivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,779 Underlying: Common Stock · 8,779 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:56 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 7,083 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001209191-23-037133 · doc4.xml · derivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,083 Underlying: Common Stock · 7,083 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 02:26 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062073 · doc4.xml · derivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2032-12-18 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant (December 19, 2022). Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 19:08 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026335 · doc4.xml · derivative · entry 1 Cardon Lon · CIK 0001854337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-07 F1 · derivative.exercise_date: The shares subject to the option vest on April 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.